Elevated levels of the TGF-β reprogramming LRRC15 + CAF signature correlated with a poor response to anti-PD-L1 therapy in six cancer types, including HNSCC [202]. This evidence concerns the gene TGFB1 and head and neck squamous cell carcinoma.